Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

Introduction A major driver of the global autologous cell therapy market is the rising demand for personalized and precision-based medical trea ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Bristol Myers sparked headlines with impressive new data for Breyanzi, its cancer therapy targeting relapsed marginal zone ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which ...

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.

These T cells are then sent to a manufacturing site where a receptor called CAR is added to them, making them Breyanzi CAR T cells. This process usually takes about three to four weeks ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...